Drew Bird, AAAAI 2021: Hot Topics in Pediatric Food Allergy
We were delighted to meet with Dr Drew Bird (Associate Professor of Pediatrics, Division of Allergy & Immunology, UT Southwestern Medical Center, Dallas, TX, USA) to discuss the current hot topics in pediatric food allergy.
The workshop entitled ‘Hot Topics in Pediatric Food Allergy‘ was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
- What have been the most important recent advances in prevention of food allergy in children? (0:22)
- What have recent study data taught us about the diagnosis and management of peanut and milk allergies? (1:22)
- Could you give us a brief overview of the latest developments in epicutaneous immunotherapy for peanut allergy? (3:02)
- What are the most promising emerging therapies for eosinophilic esophagitis? (4:25)
- What other studies from your presentation would you like to highlight? (5:40)
- Sakihara T, Otsuji K, Arakaki Y, et al. Randomized trial of early infant formula introduction to prevent cow’s milk allergy. J Allergy Clin Immunol. 2021 Jan;147(1):224-232.e8.
- Greenhawt M, Shaker M, Wang J, et al. Peanut allergy diagnosis: A 2020 practice parameter update, systematic review, and GRADE analysis. J Allergy Clin Immunol. 2020;146(6):1302-1334.
- Yonkof JR, Mikhail IJ, Prince BT, Stukus D. Delayed and severe reactions to baked egg and baked milk challenges. J Allergy Clin Immunol Pract. 2021;9(1):283-289.e2.
- Fleischer DM, Shreffler WG, Campbell DE, et al. Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results. J Allergy Clin Immunol. 2020;146(4):863-874.
- Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111-122.e10.
- Gann PH, Deaton RJ, McMahon N, et al. An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: Phase 2 trial results. J Allergy Clin Immunol. 2020;146(2):367-376.e3.
- Schroer B, Groetch M, Mack DP, Venter C. Practical challenges and considerations for early introduction of potential food allergens for prevention of food allergy. J Allergy Clin Immunol Pract. 2021;9(1):44-56.e1.
- Bird JA, Leonard S, Groetch M, et al. Conducting an oral food challenge: An update to the 2009 adverse reactions to foods committee work group report. J Allergy Clin Immunol Pract. 2020;8(1):75-90.e17.
Disclosures: Drew Bird has been a consultant for AllerGenis, Before Brands and Novartis; and has supported/contracted research in the past 12 months for Aimmune Therapeutics, Astellas, DBV Technologies, FARE, Genentech and NIH-NIAID.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
Share this Video
Related Videos In Allergic Conditions
William R. Lumry, AAAAI 2023: Lanadelumab for paediatric patients aged 2 to <12 years with hereditary angioedema – the SPRING Study
The SPRING Study (NCT04070326) was a phase 3 study that investigated the safety, pharmacokinetics, and pharmacodynamics of lanadelumab for prevention of hereditary angioedema (HAE) attacks in children. touchIMMUNOLOGY were delighted to speak with Dr. William R. Lumry (UT Southwestern Medical Center, TX, USA) around the aims, design and findings from the SPRING Study and how […]
William R. Lumry, AAAAI 2023: Current treatment paradigm and unmet needs in hereditary angioedema
Hereditary angioedema (HAE) is a rare genetic disease that reduces C1 inhibitor levels and impacts the regulation of several pathways involved in dilation of the blood vessels and results in recurrent episodes of severe swelling. touchIMMUNOLOGY were delighted to speak with Dr. William R. Lumry (UT Southwestern Medical Center, TX, USA) around the unmet needs […]
Ralph Mösges, AAAAI 2023: Mannan conjugated birch pollen allergoids for the treatment of birch pollen allergy
Mannan conjugated birch pollen allergoids are an immunotherapy currently under clinical investigation for the treatment of birch pollen allergy. touchIMMUNOLOGY caught up with Prof. Ralph Mösges (University of Cologne, Cologne, Germany) to discuss the rationale and methodology of the the clinical trial programme for Mannan conjugated birch pollen allergoids, the efficacy and safety findings so […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!